ストックスクリーナーアプリを入手
33.01
5.42%
-1.89
アフターアワーズ：
33.64
0.63
+1.91%
前日終値:
$34.90
開ける：
$34.54
24時間の取引高:
3.29M
Relative Volume:
1.19
時価総額：
$6.49B
収益：
$217.77M
当期純損益:
$-438.86M
株価収益率:
-13.70
EPS:
-2.41
ネットキャッシュフロー:
$-456.33M
1週間 パフォーマンス:
-8.94%
1か月 パフォーマンス:
+6.38%
6か月 パフォーマンス:
+14.86%
1年 パフォーマンス:
-7.35%
1日の値動き範囲:
$32.32
$35.00
1週間の範囲:
$32.32
$35.46
52週間の値動き範囲:
$21.62
$39.47
Bridgebio Pharma Inc Stock (BBIO) Company Profile
BBIO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BBIO
Bridgebio Pharma Inc
|
33.01 | 6.49B | 217.77M | -438.86M | -456.33M | -2.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.31 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
684.87 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
622.61 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.53 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
111.56 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-10-03 | 開始されました | Oppenheimer | Perform |
| 2024-09-04 | 開始されました | Piper Sandler | Overweight |
| 2024-03-21 | 再開されました | Raymond James | Outperform |
| 2024-01-31 | 開始されました | BMO Capital Markets | Market Perform |
| 2023-12-08 | 開始されました | Wells Fargo | Overweight |
| 2023-11-07 | 開始されました | Citigroup | Buy |
| 2023-10-24 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-07-18 | ダウングレード | Jefferies | Buy → Hold |
| 2023-04-19 | 開始されました | Evercore ISI | Outperform |
| 2023-02-06 | 開始されました | Cowen | Outperform |
| 2021-12-27 | 繰り返されました | Mizuho | Buy |
| 2021-12-27 | 繰り返されました | SVB Leerink | Outperform |
| 2021-09-10 | アップグレード | BofA Securities | Neutral → Buy |
| 2021-05-21 | 開始されました | UBS | Buy |
| 2021-03-22 | 繰り返されました | Goldman | Buy |
| 2021-02-22 | 再開されました | JP Morgan | Overweight |
| 2021-02-09 | 再開されました | Goldman | Buy |
| 2021-01-11 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-12-10 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-06-25 | 開始されました | BofA/Merrill | Neutral |
| 2020-05-19 | 開始されました | BTIG Research | Buy |
| 2020-04-13 | 開始されました | H.C. Wainwright | Buy |
| 2020-02-19 | 開始されました | Mizuho | Buy |
| 2019-07-26 | 開始されました | Raymond James | Outperform |
| 2019-07-22 | 開始されました | BMO Capital Markets | Outperform |
| 2019-07-22 | 開始されました | Goldman | Buy |
| 2019-07-22 | 開始されました | JP Morgan | Overweight |
| 2019-07-22 | 開始されました | Jefferies | Buy |
| 2019-07-22 | 開始されました | Piper Jaffray | Overweight |
| 2019-07-22 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Bridgebio Pharma Inc (BBIO) 最新ニュース
BridgeBio spin-out in SPAC deal to target RAS and PI3Kα malignancies - The Pharma Letter
Leerink Partnrs Has Optimistic Outlook of BBIO Q1 Earnings - MarketBeat
Y Intercept Hong Kong Ltd Increases Holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
What is Leerink Partnrs' Forecast for BBIO Q3 Earnings? - MarketBeat
BridgeBio Pharma (NASDAQ:BBIO) Shares Gap DownTime to Sell? - MarketBeat
Q1 Earnings Estimate for BBIO Issued By Leerink Partnrs - MarketBeat
Brian C. Stephenson Sells 8,500 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) Stock - MarketBeat
BridgeBio Pharma, Inc. (NASDAQ:BBIO) CEO Neil Kumar Sells 75,000 Shares - MarketBeat
Finance Watch: BridgeBio’s Oncology Spinout Reveals Go-Public Plan - Insights
BridgeBio Pharma Strengthens Financial Position with Note Issuance - TipRanks
BridgeBio Pharma Issues $575 Million Of 1.75% Convertible Senior Notes Due 2031 - Marketscreener.com
BridgeBio spinout to go public in SPAC deal with Helix Acquisition Corp. II - MSN
BridgeBio Oncology to Go Public in SPAC Deal Bringing $450M+ for Trio of Cancer Drugs - MedCity News
BridgeBio Pharma, NetApp, Talen Energy - TradingView
Raymond James resumes coverage on BridgeBio with 'outperform' on heart drug optimism - TradingView
BridgeBio oncology spinout to go public in blank-check merger - BioPharma Dive
BridgeBio Pharma's cancer-focused spinout plans $450 million deal to go public - The Business Journals
BridgeBio spinout to go public in SPAC deal (HLXB:NASDAQ) - Seeking Alpha
Helix Acquisition to Merge With BridgeBio Oncology Therapeutics -February 28, 2025 at 09:37 am EST - Marketscreener.com
$450M Deal Powers New Cancer-Fighting Biotech: What's Inside BridgeBio's Oncology SPAC Merger? - StockTitan
BridgeBio price target raised to $46 from $45 at BofA - TipRanks
BridgeBio Pharma, Inc. Investigated Regarding Potential Securities Law ViolationsContact Levi & Korsinsky for DetailsBBIO - ACCESS Newswire
BridgeBio prices offering of $500 million convertible senior notes due 2031 - MSN
BridgeBio Pharma CFO Brian Stephenson sells $282,114 in stock By Investing.com - Investing.com South Africa
BridgeBio Pharma CEO Neil Kumar sells $2.52 million in stock By Investing.com - Investing.com South Africa
BridgeBio Pharma, Inc. (BBIO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
Bayer Execs Roth And Eckhardt On Current And Future Pharma Growth - Insights
BridgeBio Pharma CFO Brian Stephenson sells $282,114 in stock - Investing.com India
BridgeBio Pharma CEO Neil Kumar sells $2.52 million in stock - Investing.com India
10 Health Care Stocks Whale Activity In Today's Session - Benzinga
BridgeBio Pharma (NASDAQ:BBIO) Sees Strong Trading VolumeStill a Buy? - MarketBeat
Principal Financial Group Inc. Reduces Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
HealthInvest Partners AB Buys 49,600 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
Latham & Watkins Advises on BridgeBio’s US$500 Million Convertible Senior Notes Offering - Latham & Watkins LLP
BridgeBio Pharma (BBIO): Among the Best Performing Mid Cap Stocks to Buy According to Analysts - Insider Monkey
BridgeBio up after $500 mln convertible debt deal priced - TradingView
BridgeBio Pharma Prices $500 Million Convertible Senior Notes Offering -February 26, 2025 at 05:59 am EST - Marketscreener.com
BridgeBio Pharma, Inc. Prices $500 Million Convertible Senior Notes Offering to Lower Debt and Enhance Financial Flexibility - Nasdaq
BridgeBio Prices Offering of $500 Million Convertible Senior Notes due 2031 to Refinance Senior Secured Debt - GlobeNewswire
How BridgeBio's $500M Debt Refinancing Could Strengthen Its Financial Future - StockTitan
When the Price of (BBIO) Talks, People Listen - Stock Traders Daily
BridgeBio Pharma (NASDAQ:BBIO) Price Target Raised to $52.00 at Scotiabank - MarketBeat
BridgeBio announces offering of convertible senior notes to refinance debt - MSN
BridgeBio's SWOT analysis: genetic disease stock poised for growth - Investing.com India
BridgeBio’s SWOT analysis: genetic disease stock poised for growth - Investing.com
Insider Sell-Offs Shake BridgeBio Pharma Stocks - TipRanks
BridgeBio Pharma (NASDAQ:BBIO) Receives Overweight Rating from Cantor Fitzgerald - MarketBeat
BridgeBio announces $500 million convertible notes offering By Investing.com - Investing.com Nigeria
BridgeBio Pharma To Offer $500 Million Convertible Senior Notes Due 2031 - TradingView
BridgeBio announces $500 million convertible notes offering - Investing.com India
BridgeBio stock falls on convertible notes offering By Investing.com - Investing.com South Africa
Bridgebio Pharma Inc (BBIO) 財務データ
収益
当期純利益
現金流量
EPS
Bridgebio Pharma Inc (BBIO) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| STEPHENSON BRIAN C | CFO and Treasurer |
Feb 25 '25 |
Sale |
33.19 |
8,500 |
282,115 |
102,464 |
| Kumar Neil | Chief Executive Officer |
Feb 25 '25 |
Sale |
33.57 |
75,000 |
2,517,971 |
5,023,447 |
6.45%
1.23%
大文字化:
|
ボリューム (24 時間):